Nuvation Bio Inc. (NUVB) intrinsic value & 10-year financials
Nuvation Bio Inc. (NUVB) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 7 fiscal years revenue grew 699.0% a year to $62.9M, with an average return on invested capital of -51.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $4.45
- Market cap
- $1.5M
- Revenue (FY2025)
- $62.9M
- Revenue growth (7-yr CAGR)
- 699.0%
- ROIC (10-yr avg)
- -51.7%
- Free cash flow (FY2025)
- —
NUVB 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $62.9M | -$204.6M | -$0.60 | — | -338.7% | -67.4% |
| FY2024 | $7.9M | -$567.9M | -$2.11 | — | -7527.3% | -118.5% |
| FY2023 | $0 | -$75.8M | -$0.35 | — | — | -17.8% |
| FY2022 | — | -$104.2M | -$0.48 | — | — | -20.4% |
| FY2021 | — | -$86.8M | -$0.44 | — | — | -15.2% |
| FY2020 | — | -$41.7M | — | — | — | -71.0% |
| FY2019 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Nuvation Bio Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Nuvation Bio Inc. has historically struggled to out-earn its cost of capital, averaging just -51.7% ROIC.
Nuvation Bio Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Nuvation Bio Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-19.93 per share.